CD Biosynsis offers cutting-edge Genome Editing Services utilizing the revolutionary CRISPR/Cas technology and other precision nucleases (TALENs, ZFNs). Our services provide researchers and industry partners with the power to precisely modify the DNA of any organism, enabling everything from simple gene inactivation to the integration of large genetic elements. We deliver full support across the experimental spectrum, including Gene Knockout for functional studies, Gene Knock-in for pathway integration, and tailored solutions for both In Vivo and Ex Vivo therapeutic applications. Our commitment is to high efficiency, minimal off-target effects, and rigorous validation for every project.
Get a QuoteGenome editing, primarily driven by CRISPR technology, allows for targeted, efficient, and irreversible changes to the genetic code. This capability is foundational for modern biological research and therapeutic development. By enabling the precise control over gene function, our services accelerate drug discovery (creating accurate disease models), metabolic engineering (optimizing biosynthesis pathways), and gene therapy (correcting disease-causing mutations). We ensure the highest level of specificity by employing optimized gRNA design and advanced delivery systems.
Permanent inactivation of target genes using CRISPR-mediated Non-Homologous End Joining (NHEJ) to study loss-of-function phenotypes.
Precise insertion of new genetic material (e.g., reporters, epitope tags, entire pathways) via Homology-Directed Repair (HDR).
Editing patient or donor cells outside the body (e.g., T-cells, HSPCs), followed by reinfusion, crucial for cell therapy development.
Direct delivery of the editing machinery into the patient or organism to modify cells inside the body, often using AAV or LNP delivery vehicles.
Our systematic workflow ensures high editing efficiency and minimal off-target effects, from design to validated cell line.
Target Selection & Design
Delivery System Optimization
Editing & Cell Isolation
Validation & QC
Define the target gene and desired modification (KO, KI, point mutation).
gRNA Design: Use proprietary algorithms to select gRNA sequences with high on-target activity and low off-target risk.
Design of the HDR template (for Knock-in projects).
Selection of optimal CRISPR components delivery method (Plasmid, mRNA, RNP).
For therapeutic projects, we optimize viral (AAV, Lentivirus) or non-viral (LNP) delivery.
Transfection/electroporation optimization for maximizing cell viability and editing efficiency.
On-Target Analysis: Sequencing (Sanger, NGS) to confirm the precise edit at the target locus.
Off-Target Analysis: NGS-based profiling to rule out unintended edits in the genome.
Functional validation (e.g., Western Blot, qPCR) to confirm the phenotypic outcome of the edit.
High-Efficacy gRNA Design
Utilizing proprietary computational tools to select gRNAs that guarantee maximum on-target editing rates across diverse cell types.
Advanced HDR Knock-in Expertise
Specialized methods to significantly boost the efficiency of Knock-in projects, crucial for pathway integration and reporter insertion.
Comprehensive QC and Validation
Rigorous use of NGS and functional assays to verify the precise edit, confirm clonality, and screen for potential off-target effects.
Therapeutic Application Focus
Expertise in both In Vivo (e.g., LNP delivery) and Ex Vivo (e.g., CAR-T cell editing) strategies for translational research.
"The Gene Knock-in service was extremely successful. CD Biosynsis efficiently inserted a 10 kb metabolic pathway into a safe harbor locus in our yeast host, providing the stable integration we desperately needed for bioproduction."
Dr. Ben Carter, R\&D Director, Sustainable Biofuels
"We relied on their In Vivo expertise for a preclinical study. Their optimized AAV delivery system achieved high editing efficiency in the target tissue with minimal toxicity, allowing us to generate reliable data quickly."
Ms. Sophia Lee, VP of Preclinical Development
"The complexity of a multi-gene Knockout project was handled seamlessly. The final monoclonal cell lines were perfectly characterized, and the off-target analysis gave us full confidence in the model’s fidelity."
Prof. Ahmed Khan, Genetic Disease Research Lab
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look toward further working with them."
Dr. Raj Patel, Principal Investigator, Department of Molecular Biology
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist, AstraZeneca Pharmaceuticals, Spain
What is the difference between Gene Knockout and Gene Knock-in ?
Gene Knockout (KO) typically uses NHEJ to disrupt a gene, resulting in a loss-of-function mutation. Gene Knock-in (KI) uses HDR to insert a defined DNA sequence (such as a reporter or a corrected gene) at a specific genomic location.
How do you minimize off-target effects ?
We minimize off-target effects through: 1) Optimized gRNA Design: Selecting sequences with minimal homology to non-target sites; 2) Delivery Method: Using RNP (Ribonucleoprotein) complexes which degrade quickly; and 3) Rigorous Validation: Performing NGS-based whole-genome or targeted off-target sequencing.
What is the purpose of Ex Vivo gene editing?
Ex Vivo editing provides a controlled environment to genetically modify cells (often stem cells or immune cells) before reintroducing them into the patient. This is the primary strategy used in current clinical trials for CAR-T cell therapies and hematopoietic stem cell therapies.
What is the advantage of using RNP (Ribonucleoprotein) over Plasmid delivery?
RNP (Cas9 protein complexed with gRNA) provides a faster, transient presence of the nuclease in the cell. This short duration significantly reduces the time window for off-target activity, resulting in higher specificity and lower toxicity compared to continuous expression from a plasmid.
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS, FDA).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.